Zelira Therapeutics Ltd Total Assets
Zelira Therapeutics Ltd total assets. Based on the latest financial reports, Zelira Therapeutics Ltd (ZLD) holds total assets worth AU$1.30 Million AUD (≈ $920.32K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ZLD company net worth for the company's overall valuation and market capitalisation.
Total Assets of Zelira Therapeutics Ltd (2004–2025)
Total assets of Zelira Therapeutics Ltd from 2004 to 2025. This chart illustrates how Zelira Therapeutics Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Zelira Therapeutics Ltd for real-time trading data and today's change.
Zelira Therapeutics Ltd - Asset Composition Analysis
Zelira Therapeutics Ltd Total Assets Breakdown (June 2025)
Zelira Therapeutics Ltd total assets breakdown as of June 2025. Zelira Therapeutics Ltd's total assets of AU$1.30 Million consist of 47.2% current assets and 52.8% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0.4% |
| Accounts Receivable | AU$4.69K | 0.4% |
| Inventory | AU$477.91K | 36.7% |
| Property, Plant & Equipment | AU$121.85K | 9.4% |
| Intangible Assets | AU$520.63K | 40.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2004–2025)
This chart illustrates how Zelira Therapeutics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Zelira Therapeutics Ltd's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zelira Therapeutics Ltd's current assets represent 47.2% of total assets in 2025, an increase from 29.4% in 2004.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 25.2% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 40.0% of total assets.
Zelira Therapeutics Ltd Competitors by Total Assets
Key competitors of Zelira Therapeutics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Zelira Therapeutics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 0.60 | 2.73 |
| Quick Ratio | 0.02 | 0.42 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 2.53 |
| Working Capital | AU$-4.98 Million | AU$-2.83 Million | AU$1.16 Million |
Zelira Therapeutics Ltd - Advanced Valuation Insights
This section examines the relationship between Zelira Therapeutics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.32 |
| Latest Market Cap to Assets Ratio | 3.58 |
| Asset Growth Rate (YoY) | -74.9% |
| Total Assets | AU$1.30 Million |
| Market Capitalization | $4.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zelira Therapeutics Ltd's assets at a significant premium (3.58x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Zelira Therapeutics Ltd's assets decreased by 74.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Zelira Therapeutics Ltd (2004–2025)
The table below shows the annual total assets of Zelira Therapeutics Ltd from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$1.30 Million ≈ $920.32K |
-74.91% |
| 2024-06-30 | AU$5.18 Million ≈ $3.67 Million |
-84.71% |
| 2023-06-30 | AU$33.89 Million ≈ $23.98 Million |
-10.11% |
| 2022-06-30 | AU$37.70 Million ≈ $26.68 Million |
-4.23% |
| 2021-06-30 | AU$39.37 Million ≈ $27.85 Million |
+9.99% |
| 2020-06-30 | AU$35.79 Million ≈ $25.32 Million |
+918.11% |
| 2019-06-30 | AU$3.52 Million ≈ $2.49 Million |
-44.33% |
| 2018-06-30 | AU$6.31 Million ≈ $4.47 Million |
-20.75% |
| 2017-06-30 | AU$7.97 Million ≈ $5.64 Million |
+9003.45% |
| 2016-06-30 | AU$87.52K ≈ $61.92K |
-78.56% |
| 2015-06-30 | AU$408.27K ≈ $288.87K |
-47.67% |
| 2014-06-30 | AU$780.16K ≈ $552.02K |
-27.66% |
| 2013-06-30 | AU$1.08 Million ≈ $763.11K |
-24.66% |
| 2012-06-30 | AU$1.43 Million ≈ $1.01 Million |
+63.54% |
| 2011-06-30 | AU$875.29K ≈ $619.33K |
+25.95% |
| 2010-06-30 | AU$694.95K ≈ $491.72K |
-80.41% |
| 2009-06-30 | AU$3.55 Million ≈ $2.51 Million |
+153.52% |
| 2008-06-30 | AU$1.40 Million ≈ $990.04K |
-84.91% |
| 2007-06-30 | AU$9.27 Million ≈ $6.56 Million |
-64.95% |
| 2006-06-30 | AU$26.45 Million ≈ $18.72 Million |
+163.92% |
| 2005-06-30 | AU$10.02 Million ≈ $7.09 Million |
+17.33% |
| 2004-06-30 | AU$8.54 Million ≈ $6.04 Million |
-- |
About Zelira Therapeutics Ltd
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more